All In Biotech

Drug Trial Radar · NCT01272037

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,018 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,018

Actual

Start

Feb 28, 2011

Primary completion

Feb 1, 2023

Study completion Jan 8, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in the breast to surrounding normal tissue (invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast cancer.

Conditions

  • Breast Ductal Carcinoma In Situ
  • Invasive Breast Carcinoma
  • Multicentric Breast Carcinoma
  • Multifocal Breast Carcinoma
  • Synchronous Bilateral Breast Carcinoma

Interventions

  • AnastrozoleDrug

    Given PO

  • ExemestaneDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • LetrozoleDrug

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies (closed as of 12/1/12)

  • Systemic ChemotherapyDrug

    Given IV

  • Tamoxifen CitrateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (IDFS)Time frame: 5 years after randomization

Locations

1,568 sites in 10 countries. Site status is shown where the registry gives one.

  • Northeast Alabama Regional Medical Center

    Anniston, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Providence Hospital

    Mobile, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Virginia G Piper Cancer Care-Del Camino

    Scottsdale, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • NEA Baptist Memorial Hospital

    Jonesboro, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • East Bay Medical Oncology Hematology Medical Associates-Antioch

    Antioch, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • Community Cancer Institute

    Clovis, California

  • University Oncology Associates

    Clovis, California

  • John Muir Medical Center-Concord

    Concord, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • Sutter Davis Hospital

    Davis, California

Showing 40 of 1,568 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.